VIR Vir Biotechnology Inc: Market Capitalization to Book Value Ratio

Official company branding of Vir Bio (VIR)

This daily price chart for Vir Biotechnology, Inc. (VIR) reflects the business dynamics of a company developing countermeasures against dangerous viruses. High barriers to entry, driven by patent protection and strict FDA oversight, constrain competition. Management efficiency is based on scientific expertise and development transparency, while market influence and the 1.99 metric are supported by government contracts and a unique immunological foundation.

Vir Biotechnology, Inc. (VIR) - Market Capitalization to Book Value Ratio from 07/04/2022 to 10/28/2026

VIR (Vir Biotechnology Inc): analytical breakdowns and indicator data

- price and consensus price forecast:
Price Chart Vir Biotechnology, Inc.|VIR - Forecast Levels Chart
- market capitalization data:
Market Capitalization Vir Bio|VIR - Value Adjusted for Debt and Cash
- book capitalization data:
Book Value per Share Vir Biotechnology|VIR - Book Capitalization|Market Value to Book Value Ratio vir.bio|VIR - Aggregate Asset Value
- debt and liquidity data:
Debt to Equity Vir Biotechnology, Inc.|VIR - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Vir Bio|VIR - Company Aggregate Debts|Debt to Book Value Vir Bio|VIR - Company Long-Term Loans and Borrowings|Company Current Liabilities Vir Biotechnology
Basic company analysis:VIR (Vir Biotechnology, Inc.)
Finished products of Vir Biotechnology Inc

Fundamental asset selection is based on comparing the market price to the actual net asset value to identify overvalued securities. This ratio measures the premium of market value over book value, which in the case of Vir Biotechnology, Inc. (VIR) confirms business resilience due to significant liquid reserves that minimize shareholder dilution, as demonstrated by the market-to-book value chart.

Main competitors

Market Value to Book Value Ratio Gilead Sciences, Inc. (GILD)|Cidara Therapeutics (CDTX) - Market Capitalization to Net Assets|NVAX - Market Capitalization to Book Value Ratio|Market Value to Book Value CureVac NV|Market Capitalization to Book Value Ratio VALN|Market Capitalization to Book Value Ratio SIGA (TPOXX)|Market Value to Book Value Ratio Emergent BioSolutions|ateapharma.com - Market Value to Book Value|IVVD: Market Value to Book Value Ratio|ENTA - Market Cap to Net Assets Ratio|INO: Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio HilleVax Inc.|KLRS - Market Cap to Net Assets Ratio|Market Value to Book Value Dyadic (DYAI)|Market Cap to Net Assets Ratio NanoViricides, Inc. (NNVC)|Market Value to Book Value Ratio Talphera Inc (TLPH)|Market Capitalization to Book Value Ratio COCP|Traws Pharma Inc - Market Capitalization to Book Value|Market Value to Book Value Ratio Virios Therapeutics (DWTX)|qualigeninc.com (QLGN) - Market Value to Book Value|ALVR: Market Cap to Net Assets Ratio|VBIV (VBI Vaccines) - Market Capitalization to Book Value Ratio|VIRI: Market Value to Book Value Ratio|Market Capitalization to Book Value Vaxart Corp (VXRT)